|
Opportunity Knocks - Target
Price Raised to $1.00
Unusual trading activity
has driven the shares of PBIO lower giving
investors further opportunity to
build their positions. Management has not
indicated to us that there have been any changes
to their business model and future projections
which we feel lends a bright future to the company
.
We are told that a
block of stock is being cleared creating
this event .
As with many small cap
stocks volatility yields opportunity .
Daily Trader
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO)
develops, markets, and sells proprietary laboratory
instrumentation and associated consumables to the
estimated $6 billion
life sciences sample preparation market.
Their products
are based on the unique properties of both constant
(i.e., static) and alternating (i.e., pressure cycling
technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between
ambient and ultra-high levels to safely and
reproducibly control bio-molecular interactions.
To date, PBIO has installed over 250 PCT systems in
approximately 160 sites worldwide. There are over 100
publications citing the advantages of the PCT platform
over competitive methods, many from key opinion
leaders.
Their primary application development and sales
efforts are in the biomarker discovery and forensics
areas. Customers also use our products in other areas,
such as drug discovery & design, bio-therapeutics
characterization, soil & plant biology, vaccine
development, histology, and forensic applications.
For more information, visit:
www.PressureBioSciences.com
|
